title: New perspectives on type I IFNs in cancer.
abstract: Although type I IFNs were initially described based on their anti-viral properties, it was quickly realized that these cytokines had anti-proliferative and anti-cancer activities. These observations ultimately led to the clinical development and utility of IFN-α2b for the treatment of patients with melanoma, renal cell carcinoma, and chronic myelogenous leukemia, among others. However, the mechanism of action of type I IFNs in vivo was never fully elucidated, and the pleiotropic effects of IFNs on multiple cell types had made it challenging to decipher. Advancement of genetically engineered mouse models has provided new tools for interrogating these mechanisms. Recent evidence has indicated that spontaneous innate immune sensing of cancers that leads to adaptive immune responses is dependent on host type I IFN production and signaling. The major innate immune receptor pathway that leads to type I IFN production in response to a growing tumor appears to be the STING pathway of cytosolic DNA sensing. STING agonists drive type I IFN production and are impressively therapeutic in mouse tumor models. Targeting low doses of type I IFNs to the tumor microenvironment also promotes anti-tumor activity via host adaptive immunity that is T cell-dependent. However, high doses of intratumoral type I IFNs largely function via an anti-angiogenic effect. Understanding these mechanistic details should enable improved clinical manipulation of the type I IFN system in cancer.
authors: Department of Pathology and Department of Medicine, Section of Hematology/Oncology, The University of Chicago, 5841 S. Maryland Ave., MC2115, Chicago, IL 60637, United States. Electronic address: tgajewsk@medicine.bsd.uchicago.edu.
authors: Thomas F
authors: TF
authors: Gajewski
authors: Department of Pathology and Department of Medicine, Section of Hematology/Oncology, The University of Chicago, 5841 S. Maryland Ave., MC2115, Chicago, IL 60637, United States.
authors: Leticia
authors: L
authors: Corrales
mesh_terms: D056704:Adaptive Immunity; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007113:Immunity, Innate; D007370:Interferon Type I / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000276:immunology; D059016:Tumor Microenvironment
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007370:Interferon Type I
references: Cancer Res. 2003 May 15;63(10):2535-45
references: 12750277
references: Cancer Immunol Immunother. 2006 Oct;55(10):1185-97
references: 16468035
references: J Immunol. 2006 Aug 1;177(3):1670-8
references: 16849476
references: Science. 2006 Sep 29;313(5795):1960-4
references: 17008531
references: Cancer Res. 2009 Apr 1;69(7):3077-85
references: 19293190
references: Nature. 2009 Oct 8;461(7265):788-92
references: 19776740
references: Expert Opin Investig Drugs. 2010 Feb;19(2):295-304
references: 20050824
references: Cancer J. 2010 Jul-Aug;16(4):399-403
references: 20693853
references: N Engl J Med. 2010 Aug 19;363(8):711-23
references: 20525992
references: Cancer Res. 2011 Apr 1;71(7):2488-96
references: 21300764
references: J Exp Med. 2011 Sep 26;208(10):2005-16
references: 21930765
references: J Exp Med. 2011 Sep 26;208(10):1989-2003
references: 21930769
references: J Transl Med. 2012;10:1
references: 22214470
references: Cancer Immunol Immunother. 2012 Jul;61(7):1019-31
references: 22146893
references: N Engl J Med. 2012 Jun 28;366(26):2443-54
references: 22658127
references: Trends Immunol. 2013 Feb;34(2):67-73
references: 23122052
references: Curr Opin Immunol. 2013 Apr;25(2):268-76
references: 23579075
references: J Immunol. 2013 May 15;190(10):5216-25
references: 23585680
references: Cell. 2013 Aug 15;154(4):748-62
references: 23910378
references: Sci Transl Med. 2013 Aug 28;5(200):200ra116
references: 23986400
references: Nat Immunol. 2013 Oct;14(10):1014-22
references: 24048123
references: Cancer Cell. 2014 Jan 13;25(1):37-48
references: 24434209
references: J Immunol. 2014 Oct 15;193(8):4254-60
references: 25217157